Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Healthcare | Small Cap
Health Score : 7.51Beta Drugs Ltd. shows a picture of strong financial health, marked by exceptional profitability and impressive growth. The company has a very stable foundation with very little reliance on debt. It is successfully expanding its sales and profits, indicating high demand for its services in the healthcare sector. However, a key area of concern is its operational efficiency. The company takes a long time to convert its inventory into sales and is particularly slow in collecting payments from its customers. This can tie up cash that could be used elsewhere. The future outlook points towards continued expansion, but its success will also depend on how it manages its day-to-day operations.
Health Score : 7.51Beta Drugs Ltd. shows a picture of strong financial health, marked by exceptional profitability and impressive growth. The company has a very stable foundation with very little reliance on debt. It is successfully expanding its sales and profits, indicating high demand for its services in the healthcare sector. However, a key area of concern is its operational efficiency. The company takes a long time to convert its inventory into sales and is particularly slow in collecting payments from its customers. This can tie up cash that could be used elsewhere. The future outlook points towards continued expansion, but its success will also depend on how it manages its day-to-day operations.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
110.66
Industry Median
36.13
Small Cap Median
35.79
P/E RATIO
40.27
P/B RATIO
8.68
Industry Median
6.08
Small Cap Median
6.08
P/S RATIO
7908.46
Industry Median
5.75
Small Cap Median
5.17
Others
PEG RATIO
1.09
EV/EBITDA RATIO
21.93
Growth Score : 10.00The company is experiencing an exceptional period of growth across all key areas. It is successfully increasing its revenues, profits, and asset base at a very impressive rate. This demonstrates strong market demand, effective business strategy, and a solid foundation for future expansion. This robust growth is a primary strength, indicating the company is performing very well in its market and is on a strong upward trajectory.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 58.62 | 23.37 | 30.4 | 22.3 | 6.35 |
| Operating Profit Growth Rate | 72 | 23.26 | 13.21 | 25 | 1.33 |
| Earnings Per Share (EPS) Growth | 111.9 | 23.76 | 18.61 | 16.46 | -2.62 |
| Asset Growth Rate | 33.9 | 25.32 | 28.28 | 71.65 | 13.76 |
| Net Income Growth Rate | 108.33 | 24 | 16.13 | 16.67 | -2.38 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Jagsonpal Pharmaceuticals Ltd | 8.51 | 37.27 | Overvalued | 58.00 | 6.54 | 43.00 |
| 2 | Amrutanjan Health Care Ltd | 8.25 | 70.69 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 3 | Windlas Biotech Ltd | 7.52 | 32.03 | Neutral | 105.00 | 32.19 | 66.00 |
| 4 | Beta Drugs Ltd | 7.51 | 40.27 | Neutral | 76.00 | 12.93 | 41.00 |
| 5 | Syncom Formulations (India) Ltd | 6.92 | 24.78 | Neutral | 77.00 | 0.81 | 76.00 |
| 6 | Hester Biosciences Ltd | 6.54 | 33.64 | Neutral | 87.00 | 61.24 | 57.00 |
| 7 | Sigachi Industries Ltd | 6.49 | -14.82 | Neutral | 54.00 | -2.08 | -83.00 |
| 8 | SMS Pharmaceuticals Ltd | 5.94 | 33.82 | Neutral | 171.00 | 9.35 | 102.00 |
| 9 | Tarsons Products Ltd | 5.90 | 127.92 | Neutral | 118.00 | 4.26 | 14.00 |
| 10 | Shalby Ltd | 5.85 | 44.41 | Undervalued | 143.00 | 10.45 | 35.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Beta Drugs Ltd is an India-based pharmaceutical company specializing in manufacturing, marketing, and distribution of oncology products. It also produces general medicines, critical care drugs, and neutraceuticals, catering to various therapeutic segments. The company focuses on expanding its product portfolio and market reach within the domestic pharmaceutical landscape.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Beta Drugs Ltd's P/E ratio (TTM) is 110.66, compared to the industry median of 36.13 and large cap median of 35.79.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Beta Drugs Ltd's P/B ratio is 8.68, compared to the industry median of 6.08 and large cap median of 6.08.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Beta Drugs Ltd's P/S ratio is 7908.46, compared to the industry median of 5.75 and large cap median of 5.17.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Beta Drugs Ltd's PEG ratio is 1.09.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Beta Drugs Ltd's EV/EBITDA ratio is 21.93.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Beta Drugs Ltd's ROE is 16.73%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Beta Drugs Ltd's ROA is 15.32%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Beta Drugs Ltd's ROCE is 19%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Beta Drugs Ltd's operating margin is 19.74%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Beta Drugs Ltd's net margin is 10.65%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Beta Drugs Ltd's current ratio is 3.17.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Beta Drugs Ltd's debt-to-equity ratio is 0.54.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Beta Drugs Ltd's interest coverage ratio is 4.60.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Beta Drugs Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Beta Drugs Ltd's EPS is -2.62.
(Source line: "Ratios as of 11 Oct 2026, based on last traded price of ₹N/A. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 2005
Headquarters: Chandigarh, Punjab
Core Offerings: Oncology formulations, General medicines, Critical care products, Pharmaceutical contract manufacturing, Nutraceuticals
Stock Listing: NSE (BETA), BSE ({bse})
Promoter: Rahul Batra / Beta Drugs Promoter Group
Beta Drugs Ltd was incorporated in 2005, primarily focusing on the manufacturing and marketing of pharmaceutical formulations. Over the years, the company strategically expanded its product portfolio, with a significant emphasis on the high-growth oncology segment. It successfully listed on the NSE Emerge platform in 2017, subsequently migrating to the NSE main board. The company continues to invest in R&D and manufacturing capabilities to strengthen its market position.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Pharmaceutical Formulations | 100% | N/A (company primarily operates in a single reportable segment) |
Oncology Products: A key focus area, manufacturing a wide range of cancer-related medications, contributing significantly to revenue.
General & Critical Care: Offers various therapeutic segments including anti-infectives, pain management, cardiac, and diabetic drugs, alongside critical care formulations.
Contract Manufacturing: Engages in third-party manufacturing for other pharmaceutical companies, leveraging its production facilities.
Nutraceuticals: Diversifies into health and wellness products, offering dietary supplements.
Mr. Rahul Batra - Chairman & Managing Director. He is the founder of Beta Drugs and has extensive experience in the pharmaceutical industry, guiding the company's strategic growth and operational excellence.
No major subsidiaries reported.
Bonus Issue: 1:1 Bonus Shares issued in October 2023.
The Beta Drugs Ltd share price today is ₹N/A on NSE (BETA), as of 11 Oct 2026.
As of 11 Oct 2026, Beta Drugs Ltd share price is ₹N/A, with previous close ₹N/A. Today's range is ₹N/A to ₹N/A. The 52-week range is ₹N/A to ₹N/A.
As of today, Beta Drugs Ltd's market cap is ₹2,083.13 Cr crore (Small Cap).
Beta Drugs Ltd's current P/E ratio is 110.66, compared to the Healthcare Services (Hospitals & Diagnostics) sector average of 42.
Beta Drugs Ltd's current P/B ratio is 8.68.
Beta Drugs Ltd's current dividend yield is N/A. Last dividend of ₹1.00 per share was declared on 27-Sep-2023.
Beta Drugs Ltd's EPS (TTM) is ₹-2.62.
Beta Drugs Ltd is an India-based pharmaceutical company specializing in manufacturing, marketing, and distribution of oncology products. It also produces general medicines, critical care drugs, and neutraceuticals, catering to various therapeutic segments. The company focuses on expanding its product portfolio and market reach within the domestic pharmaceutical landscape.
Beta Drugs Ltd is promoted by Rahul Batra / Beta Drugs Promoter Group, holding 64.63% as of 11 Oct 2026.
Beta Drugs Ltd is listed on NSE (BETA) and BSE ({bse}). Its next quarterly results are expected on August 2024 (for Q1 FY25).
Debt Ratio
